Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Genetic Testing × Breast × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 14 Ovarian Neoplasms 3 Colorectal Neoplasms 3 Neoplasms, Unknown Primary 2 Hereditary Breast and Ovarian Cancer Syndrome 2 Carcinoma, Intraductal, Noninfiltrating 2 Brain Neoplasms 2 Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8 1 Urogenital Neoplasms 1 Primary Ovarian Insufficiency 1 Neoplastic Syndromes, Hereditary 1 Neoplasm Metastasis 1 Hot Flashes 1 Head and Neck Neoplasms 1 HER2-positive Breast Cancer 1 Digestive System Neoplasms 1 Depression 1 Colorectal Neoplasms, Hereditary Nonpolyposis 1 Central Nervous System Neoplasms 1 Cardiovascular Diseases 1 Breast Screening 1 Breast Carcinoma In Situ 1 Anatomic Stage II Breast Cancer AJCC v8 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Trastuzumab 33 pertuzumab 18 Docetaxel 16 pyrotinib 15 Paclitaxel 7 Capecitabine 6 tucatinib 5 Carboplatin 5 Ado-Trastuzumab Emtansine 4 trastuzumab deruxtecan 3 neratinib 3 atezolizumab 2 Protons 2 Fulvestrant 2 pegfilgrastim 1 palbociclib 1 margetuximab 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Hospital Information Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04638725 2022-08-03

SIGHER

Institut de cancérologie Strasbourg Europe

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡